Products for Research Use Only

Icotinib

CAT: 0804-HY-15164A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15164A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CAS Number
610798-31-7
Product Name Alternative
BPI-2009
UNSPSC
12352005
Hazard Statement
H302
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/icotinib.html
Concentration
10mM
Purity
99.96
Solubility
DMSO : ≥ 155 mg/mL
Smiles
C#CC1=CC(NC2=C(C=C(OCCOCCOCCO3)C3=C4)C4=NC=N2)=CC=C1
Molecular Formula
C22H21N3O4
Molecular Weight
391.42
Precautions
H302
References & Citations
[1]Tan F, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012 May;76 (2) :177-82.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Citation 01
Breast Cancer Res Treat. 2025 Jun;211 (2) :467-478.|Cell Rep Med. 2023 Feb 21;4 (2) :100911.|Clin Chim Acta. 2022 Feb 15:527:1-10.|Eur J Pharmacol. 2019 May 5:850:141-149.|J Pharm Biomed Anal. 2023 May 10:228:115275.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Biochem Pharmacol. 2016 Dec 1:121:67-77.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Science. 2017 Dec 1;358 (6367) :eaan4368.

Popular Products